MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2018 International Congress

    Closed Loop Programming Evaluation Using External Responses for Deep Brain Stimulation (CLOVER-DBS)

    F. Sasaki, G. Oyama, S. Sekimoto, R. Nakamura, T. Jo, H. Iwamuro, A. Umemura, Y. Shimo, N. Hattori (Tokyo, Japan)

    Objective: To assess the feasibility and efficacy of a novel closed-loop programming algorithm (CLPA) for deep brain stimulation (DBS) based on objective feedback using a…
  • 2018 International Congress

    It takes two to tango but following may be more beneficial for rehabilitating people with mild-moderate Parkinson’s

    M. Hackney, A. Hart, C. Kim (Atlanta, GA, USA)

    Objective: This study determined the efficacy of internally guided (leading) versus externally guided (following) in adapted tango versus a contact-matched control group (wellness education) for…
  • 2018 International Congress

    Oral treatment with sphingosine-1-phosphate receptors modulator prevents Parkinson symptoms concomitantly to reduced brain inflammation in MPTP mouse models

    M. Cyr, E. Pépin, G. Massicotte (Trois-Rivieres, QC, Canada)

    Objective: Here we explore the efficacy of an oral treatment with Fingolimod (FTY720), a selective sphingosine-1-phosphate receptors modulator, to prevent MPTP induced nigrostriatal loss and…
  • 2018 International Congress

    Acute efficacy and tolerability of the COMT inhibitor opicapone

    F. Gandor, D. Sykora, D. Gruber, G. Ebersbach (Beelitz-Heilstätten, Germany)

    Objective: Evaluation of the acute efficacy and tolerability of Opicapone. Background: Opicapone is a Catechol-O-Methyltransferase (COMT) inhibitor for the treatment of patients with idiopathic Parkinson’s…
  • 2018 International Congress

    Characteristics of dopaminergic treatments in advanced Parkinson’s before levodopa-carbidopa intestinal gel infusion: Data from 107 tested patients

    J. Szasz, V. Constantin, K. Orban-Kis, L. Bancu, D. Georgescu, J. Szederjesi, I. Mihaly, S. Szatmari (Tirgu Mures, Romania)

    Objective: To describe the characteristics of dopaminergic treatments in a large group of patients with advanced Parkinson’s Disease (APD) in which current non-invasive therapy (oral,…
  • 2018 International Congress

    Effects of Expiratory Muscle Strength Training and Voice Therapy on Parkinsonian Speech

    T.S. Tong, M.W. Ng (Pokfulam, Hong Kong)

    Objective: The current study compared the effects of expiratory muscle strength training (EMST) and EMST plus voice therapy (VT) on speech loudness and intelligibility of…
  • 2018 International Congress

    A novel non-nitrocatechol COMT inhibitor ODM-104 shows superior pharmacodynamic effects to entacapone

    S. Janhunen, J. Venäläinen, J. Kaskinoro, L. Saloranta, J. Tuunainen (Turku, Finland)

    Objective: ODM-104 is a novel non-nitrocatechol catechol-O-methyltransferase (COMT) inhibitor that is undergoing clinical evaluation for Parkinson’s disease (PD). This study investigated the pharmacodynamic effects of…
  • 2018 International Congress

    Multimodal evoked potential analysis in Woodhouse-Sakati Syndrome

    A.H. Abusrair, I. AlHamoud, S. Bohlega (Riyadh, Saudi Arabia)

    Objective: Investigate Woodhouse-Sakati syndrome through analysis of multimodal evoked potentials at various clinical stages, to assess their possible role as an aid in determining the…
  • 2018 International Congress

    Movement disorder masquerading as seizure disorder

    K. Ganesh (Madurai, India)

    Objective: The main objective of presenting this case report is to emphasise the importance of accurate clinical diagnosis of movement disorder in children which many…
  • 2018 International Congress

    Juvenile parkinsonism associated with a novel HSD17B10 mutation in a patient with HSD10 disease

    M. Rosário, O. Moldovan, S. Reimão, I. Chendo, J. Crawford, M. Rosa, L. Guedes (Lisbon, Portugal)

    Objective: We describe the case of a female patient with HSD10 disease associated with parkinsonism, with a novel mutation in the HSD17B10 gene. Background: HSD10…
  • « Previous Page
  • 1
  • …
  • 133
  • 134
  • 135
  • 136
  • 137
  • …
  • 177
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An atypical and interesting feature of Parkinson´s disease
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley